About This Reference

What Agility Peptide is

Agility Peptide is an independent editorial reference covering the published research on four peptides studied for recovery and tissue repair: BPC-157, TB-500, GHK-Cu, and KLOW, with BPC-157 as the lead compound. The site exists to make a scattered, frequently overstated and technically demanding literature legible — to give a reader, in plain language and with citations, a clear account of what each compound was actually studied for, in which species, at what effect sizes, and how far that evidence actually reaches.

The organizing rationale is that these four entries approach repair from complementary mechanistic angles — angiogenesis (BPC-157), cytoskeletal dynamics and cell migration (TB-500/Tβ4), matrix synthesis and copper delivery (GHK-Cu), and inflammatory-signal suppression (KPV in the KLOW blend) — so that reading them together gives a fuller picture than any one alone. Each compound has its own page; a comparison page lines them up side by side; a shared references list aggregates every cited source.

How it is compiled

Three principles govern what appears here.

First, every research claim is anchored to the peer-reviewed literature. Each claim is tied to a numbered citation from PubMed-indexed journals, reviews and clinical-trial reports, with DOIs or PubMed/PMC links collected on the references page. Where a finding comes from a review rather than a primary study, the review is cited as such.

Second, evidence is reported at its true strength. Doses are described exactly as studied — for example, studied at 2 mg/kg in male Wistar rats — never scaled to humans or offered as a recommendation. Where evidence is preclinical, single-lab, or rests on a parent molecule rather than the marketed compound (as with TB-500 relative to full-length Tβ4), the page says so plainly. That candor about limits is the point of this reference, not an afterthought.

Third, pages are cross-referenced. Because the same themes — angiogenesis, actin-driven migration, collagen synthesis, NF-kB inflammation — recur across compounds, the pages link to one another so a reader can follow a mechanism from one entry to the next.

What it is not

Agility Peptide is not a store, not a clinic, and not a source of medical advice. It does not sell, supply, source, or broker any peptide or research chemical, and it has no affiliate or referral relationship with any vendor. It does not employ clinicians, diagnose conditions, or prescribe anything. It does not recommend a dose, schedule, or route of administration for any person, and it never presents an animal-study dose as something a human should take.

The compounds discussed here are research chemicals. None is an approved medicine for systemic human use; two (BPC-157, TB-500) are explicitly prohibited in sport. The KLOW blend contains TB-500 and is therefore off-limits in any anti-doping-regulated context. Readers with clinical interests should consult a licensed clinician in their own jurisdiction working with regulated, evidence-based options. The value this site offers is a calm, data-forward map of the published literature — nothing more.